Currently, the combination of anti-CD27 (varlilumab) with anti-CTLA-4 (ipilimumab) or anti-PD-1 (nivolumab) is investigated in respectively patients with melanoma (NCT02413827) and solid tumors (NCT02335918) in phase I/II studies. Here, CTLA4 is linked to melanoma.